Maddy L. Newby

This study shows that xenoglycosylation of HIV-1 Env with core (1,3)-fucose enhances cross-clade neutralization and diversifies human antibody lineages.

This paper develops a consensus HCV E1E2 antigen that engages germline B cell precursors of broadly neutralizing antibodies.

The paper maps glycan composition across HIV-1 pseudoviruses to show how sequence diversity affects the glycan shield and its vulnerability to broadly neutralizing antibodies.

This study shows that STT3A is more critical than STT3B for HIV-1 Env glycosylation, affecting virus production and antibody sensitivity.

The paper designs, characterizes, and tests a soluble HCV E1E2 heterodimer and self-assembling nanoparticles for vaccine development.

This study shows a novel two-step mechanism for inducing broadly neutralizing HIV antibodies in macaques using a modified SHIV, informing vaccine design.

This paper identifies sequence determinants that regulate oligosaccharyltransferase (OST) catalytic efficiency and glycosylation specificity in proteins.

This paper identifies Mann-type DLBCL as a subtype of GCB-DLBCL characterized by oligomannose-type glycans in CDR-located AGS, associated with poor prognosis and distinct gene expression patterns.

This study rationally designs and characterizes filovirus glycoproteins and nanoparticles in vitro and in vivo to aid vaccine development.

This study stabilizes an HIV-1 clade C trimer using multiple platforms and shows improved antigenic and immunogenic properties.

This study compares antibody responses in haemodialysis patients after vaccination with different platforms, finding mRNA vaccines induce better functional responses than viral vectors.

The paper examines how natural variations in SARS-CoV-2 glycan sites affect spike protein dynamics and antigenic structure through molecular dynamics and structural modeling.